After Merck Stops Study, What Remains Of The Alzheimer's Drug Pipeline?

By: via Benzinga
Merck & Co, Inc. (NYSE: MRK) Tuesday reported it was halting its Phase 3 study of Alzheimer's treatment verubecestat in people ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.